Shionogi’s Brisk Crestor Sales Help It Buck Industry Tide Of Lower Earnings
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bolstered by strong global sales of its blockbuster cholesterol agent Crestor, marketed by AstraZeneca, Shionogi forecast Nov. 5 that it expected a 20 percent profit jump for the full business year ending next March. The company stands out among leading Japanese drug makers for reporting income gains for both the full year and half-year ended in September
You may also be interested in...
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
TOKYO - Shionogi moved Sept. 1 to establish a sales presence in the U.S. through the acquisition of Atlanta-based Sciele Pharma. Boards of both firms approved the $1.42 billion purchase, for $31 per share, prior to the announcement
Shionogi Expects Crestor To Overtake Pfizer’s Lipitor
TOKYO - Shionogi & Co. of Osaka is projecting domestic sales of its cholesterol treatment Crestor (rosuvastatin) to grow 82 percent in fiscal 2008 to ¥19 billion ($180 million), thanks to its lower price and additional efficacy compared to competitor Pfizer's Lipitor (atorvastatin), a company official said July 2
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories